Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

This paper reports a single case of lichenoid cutaneous sarcoidosis that was unresponsive to standard treatments but showed marked improvement with the administration of oral tranilast.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

In this open-label study, participants reported that the LustrivaTM BH-002 two-step system improved various aspects of hair, skin, and nail health and appearance after three months of use.

This report describes five patients who experienced hair loss with discomfort and scarring after undergoing salon hair relaxer treatments, regardless of whether 'lye' or 'no lye' products were used.

This study reported an unusual case of nail matrix involvement and trachyonychia in a child with juvenile pityriasis rubra pilaris, showing significant improvement with topical therapy and oral biotin.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This study introduced a rapid rehydration approach for creating customizable, multifunctional hydrogel sensors, enabling precise detection of surface deformations and easy integration of layers, highlighting its potential for standardized and adaptable manufacturing of wearable devices.

This study found that after 15 months of treatment with ritlecitinib, patients with alopecia areata and less than 95% initial hair loss experienced significant hair regrowth, though those with more extensive hair loss showed more variable improvement.

This study found that ion-paired solutions significantly improved the skin penetration of risedronate in hairless mice compared to risedronate alone.

This study found that a single application of 'Lye' or 'No-Lye' chemical straighteners significantly reduced drug concentrations in hair samples from both drug-fortified standards and authentic drug users.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This extensive review discusses the clinical manifestations, potential associations, and treatment approaches for lichen planus, but reports no new clinical results, highlighting gaps in evidence for therapeutic strategies.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

In this study, a topical cream containing 3% lactic acid ferment lysate (VHProbi ® MixP) was found to significantly reduce sebum, porphyrin levels, and pore size, while increasing hydration and improving skin texture in participants with oily skin over a 60-day period.

This paper presents a therapeutic approach with excellent results in a case of lichen planopilaris overlapping with dermatomyositis and scleroderma, although broader applicability is not discussed.

This study introduced the Lichen Planus Activity and Damage Index (LiPADI), which effectively assesses the severity and progression of lichen planus, aligning well with other clinical indicators.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This study developed the TLMG hydrogel, a seamless in situ biointerface platform, demonstrating robust adhesion, high conductivity, and therapeutic effects for intelligent wound management in complex animal models and human tests, indicating its promise for integrated bioelectronic medicine.

In this study, patients with mild to moderate scalp seborrheic dermatitis experienced greater improvements in severity scores and quality of life with Lulican™ shampoo compared to Ketoconazole over four weeks, with similar safety profiles but better tolerability and cosmetic acceptability for LulicanTM.

This review summarizes recent findings on the role of lactylation, a novel post-translational modification, in skin diseases, suggesting its potential as a therapeutic target by linking metabolism, epigenetic regulation, and inflammatory processes.

This study found that patients receiving active ritlecitinib doses reported greater satisfaction with hair growth compared to placebo, with high agreement observed between clinician evaluations of scalp hair improvement and patient satisfaction through week 48.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

This case report found that a novel botanical treatment halted disease progression and promoted hair regrowth in four patients with lichen planopilaris, indicating potential for use as a safe alternative therapy.